Response to: 'Correspondence on 'SARS-CoV-2 antibody response after COVID-19 in patients with rheumatic disease'' by C et al

Ann Rheum Dis. 2023 Jun;82(6):e131. doi: 10.1136/annrheumdis-2021-220166. Epub 2021 Mar 10.
No abstract available

Keywords: COVID-19; biological therapy; rituximab.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Letter
  • Comment

MeSH terms

  • Antibody Formation
  • COVID-19*
  • Humans
  • Rheumatic Diseases* / complications
  • Rituximab
  • SARS-CoV-2
  • Vaccination

Substances

  • Rituximab